Changes in plasma concentrations of osteoprotegerin before and after levothyroxine replacement therapy in hypothyroid patients

National Medical Journal of China

Volumn 87, Issue 30, 2007, Pages 2121-2125

  Xiang, Guang Da ^a   Sun, Hui Ling ^a   Zhao, Lin Shuang ^a   Hou, Jie ^a   Yue, Ling ^a  

^a WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

Author keywords

Hypothyroidism; Osteoprotegerin; Vascular endothelial function

Indexed keywords

LEVOTHYROXINE; LIOTHYRONINE; OSTEOPROTEGERIN; THYROTROPIN; THYROXINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; LIOTHYRONINE BLOOD LEVEL; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; THYROID FUNCTION; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASODILATATION;

ADULT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPOTHYROIDISM; OSTEOPROTEGERIN; THYROXINE; TREATMENT OUTCOME; TRIIODOTHYRONINE;

EID: 35648970621     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Simonet WS, Lacey DL, Dunstan CR, et al. OsteoProtegerin: a novel secreted protein involved in the regulation of bone density. Cell, 1997, 89: 309-319.
2. Zhang J, Fu M, Myles D, et al. PDGF induces osteopretegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Letters, 2002, 21: 180-184.
3. Jano S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation, 2002, 106: 1192-1194.
4. Hak AE, Pols HA, Visser TJ, et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam study. Ann Intern Med, 2000, 132: 270-278.
5. Wren JC. Thyroid function and coronary atheresclerosis. J Am Geriatr Soc, 1968, 16: 696-704.
6. Nagasaki T, Inaba M, Jono S, et al. Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function. Eur J Endocrinol, 2005, 152: 347-353.
7. Xiang GD, Wu YH. Apolipoprotein e4 allele and endothelium-dependent arterial dilation in type 2 diabetes mellitus without angiopathy. Diabetologia, 2003, 46: 514-519.
8. Xiang GD, Wang YL. Regular aerobic exercise training improves endothelium-dependent artery dilation in patients with impaired fasting glucose. Diabetes Care, 2004, 27:801-802.
9. Papaioannou GI, Lagasse M, Mather JF, et al. Treating hypothyroidism improves endothelial function. Metabolism, 2004, 53:278-279.
10. Taddei S, Caraccio N, Virdis A, et al. Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clini Endocr Metab, 2003, 88: 3731-3737.
11. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clini Endocr Metab, 2001, 86: 631-637.
12. Malyankar UM, Scatena M, Suchland KL, et al. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem, 2000, 275: 20959-20962.
13. Bucay N, Sarosi I, Dunstun CR, et al. Osteoprotegerin-deficient mice develop early onset osteoperosis and arterial calcification. Genes Dev, 1998, 12: 1260-1268.
14. Min H, Morony S, Sarosi I, et al. Osteoprotegerin reverses osteoporesis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med, 2000, 192: 463-474.
15. Hofbauer LC, Kluger S, Kuhne CA, et al. Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. J Cell Biochem, 2002, 86: 642-650.
16. Engler H, Riesen W. Effect of thyroid function on concentration of lipeprotein (a). Clin Chem, 1993, 39: 2466-2469.